IBRX: ImmunityBio Inc - Common Stock

IBRX新闻

• 15:56 Avis Brings Back The Short Squeeze — Navitas, Beyond Meat Join In - Beyond Meat (NASDAQ:BYND), Avis Budge
• 11:49 Reframing ImmunityBio: The Long-Term Platform Opportunity Beyond Anktiva (NASDAQ:IBRX)
• 18:54 IBRX Stock Rises 7% on Strong Q1 2026 Preliminary Results
• 18:11 Why Is ImmunityBio Stock Rallying Thursday? - ImmunityBio (NASDAQ:IBRX)
• 12:58 IBRX Responds to FDA Warning Over Misleading Cancer Drug Claims
• 20:25 ImmunityBio: No Need To Rush Into Buying Today - Why I'm Downgrading To Hold (NASDAQ:IBRX)
• 13:11 ImmunityBio vs. Moderna: Which Biotech Has More Upside Potential?
• 14:04 ImmunityBio Lead Bladder Cancer Drug Trial Clears Power Check - ImmunityBio (NASDAQ:IBRX)
• 15:30 Why Is ImmunityBio (IBRX) Down 35.8% Since Last Earnings Report?
• 12:23 IBRX Stock Slides on FDA Warning Over Misleading Cancer Drug Claims
• 17:45 “FDA Warning” on Cancer Drug Sends ImmunityBio Stock (IBRX) Tumbling over 26% - TipRanks.com
• 16:44 ImmunityBio Rises on China Nod to Bladder Cancer Combo Therapy
• 15:04 ImmunityBio Crashes On FDA Warning Over Anktiva Claims - ImmunityBio (NASDAQ:IBRX)
• 13:57 Can Anktiva's Label Expansion Unlock the Next Growth Phase for IBRX?
• 20:39 ImmunityBio's Anktiva Could See More Upside: My Updated Thoughts On Expansion
• 12:41 Will Anktiva Continue to Drive ImmunityBio's Top-Line Growth in 2026?
• 11:38 NCCN扩大膀胱癌指南范围,纳入ImmunityBio药物